EGFR and non-small cell lung carcinoma: Therefore, we conducted a meta‐analysis of the randomized controlled trials to compare the efficacy between adjuvant EGFR‐TKIs and placebo/chemotherapy in EGFR mutation‐positive NSCLC patients.